TriSalus Life Sciences, Inc. (TLSI)

Market Cap	124.10M
Revenue (ttm)	26.89M
Net Income (ttm)	-56.25M
Shares Out	30.49M
EPS (ttm)	-2.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,020
Open	4.170
Previous Close	4.120
Day's Range	3.900 - 4.298
52-Week Range	3.330 - 10.420
Beta	0.50
Analysts	Strong Buy
Price Target	12.10 (+197.3%)
Earnings Date	Nov 14, 2024

About TLSI

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced panc...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: TLSI
• Website: https://trisaluslifesci.com

Financial Performance

In 2023, TriSalus Life Sciences's revenue was $18.51 million, an increase of 49.31% compared to the previous year's $12.40 million. Losses were -$63.28 million, 26.5% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for TLSI stock is "Strong Buy." The 12-month stock price forecast is $12.1, which is an increase of 197.30% from the latest price.

Price Target

$12.1

(197.30% upside)

Analyst Consensus: Strong Buy